|Articles|June 21, 2023
AAV Manufacturing: The benefits of growing serum-free, suspension HEK293 cells in the scale-X™ fixed-bed bioreactor
Author(s)Univercells Technologies
In this study, HEK293F cells grown in scale-X bioreactor produce >3x higher AAV-2 vector, with 25-52% lower cost than the reference process.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How Biopharma Navigates the 2026 Economic Shift
2
EC’s High-Dose Aflibercept Approval Highlights Durable Anti-VEGF Retinal Therapy
3
Beyond Transactional: Collaborative Partnerships for Rapid, Flexible Biologics Development
4
Agenus Closes $141 Million Immunotherapy Collaboration with Zydus Lifesciences
5